Necroptosis in anti-viral inflammation by Nailwal, Himani & Chan, Francis Ka-Ming
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2019-1 
Necroptosis in anti-viral inflammation 
Himani Nailwal 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Hemic and Immune Systems Commons, Immunity Commons, Immunology of Infectious 
Disease Commons, Immunopathology Commons, Pathological Conditions, Signs and Symptoms 
Commons, Pathology Commons, and the Viruses Commons 
Repository Citation 
Nailwal H, Chan FK. (2019). Necroptosis in anti-viral inflammation. Open Access Articles. https://doi.org/
10.1038/s41418-018-0172-x. Retrieved from https://escholarship.umassmed.edu/oapubs/3744 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
Cell Death & Differentiation
https://doi.org/10.1038/s41418-018-0172-x
REVIEW ARTICLE
Necroptosis in anti-viral inﬂammation
Himani Nailwal1 ● Francis Ka-Ming Chan 1
Received: 29 March 2018 / Revised: 8 June 2018 / Accepted: 10 July 2018
© The Author(s) 2018. This article is published with open access
Abstract
The primary function of the immune system is to protect the host from invading pathogens. In response, microbial pathogens
have developed various strategies to evade detection and destruction by the immune system. This tug-of-war between the
host and the pathogen is a powerful force that shapes organismal evolution. Regulated cell death (RCD) is a host response
that limits the reservoir for intracellular pathogens such as viruses. Since pathogen-speciﬁc T cell and B cell responses
typically take several days and is therefore slow-developing, RCD of infected cells during the ﬁrst few days of the infection
is critical for organismal survival. This innate immune response not only restricts viral replication, but also serves to promote
anti-viral inﬂammation through cell death-associated release of damage-associated molecular patterns (DAMPs). In recent
years, necroptosis has been recognized as an important response against many viruses. The central adaptor for necroptosis,
RIPK3, also exerts anti-viral effects through cell death-independent activities such as promoting cytokine gene expression.
Here, we will discuss recent advances on how viruses counteract this host defense mechanism and the effect of necroptosis
on the anti-viral inﬂammatory reaction.
Facts
● Necroptosis is mediated through cellular RHIM domain-
containing proteins, RIPK1, RIPK3, ZBP1, and TRIF.
● Virus infections activate RHIM-dependent necroptosis
in host, which leads to anti-viral inﬂammation.
● Viruses modulate necroptosis pathway through various
inhibitors competing for RHIM binding.
● RIPK3 activates the NLRP3 inﬂammasome in certain
RNA virus infection independent of its necroptotic
function.
Open questions
● Is necroptosis a primary driver or secondary form of cell
death upon virus infection?
● Do lytic viruses like IAV activate necroptosis contribute
to pathogenesis?
● Is ZBP1 sensing of viral RNA a common phenomenon
among different virus infections?
● Does RIPK3 have roles beyond necroptosis in virus
infections?
● Can targeting cellular RHIM proteins be an effective
strategy as anti-viral therapeutics?
Introduction
Regulated cell death (RCD) constitutes an important aspect
of organismal development. RCD drives crucial cellular
responses and is especially important for immune home-
ostasis. Until recently, apoptosis was synonymous with
programmed cell death. Apoptosis is characterized by cell
shrinking, chromatin condensation, nuclear fragmentation
(karyorrhexis) and plasma membrane blebbing. Apoptotic
cells also expose the “eat-me” signal phosphatidyl serine on
the cell surface to promote engulfment by resident phago-
cytes. Thus, apoptosis can be considered a “contained” and
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immunologically silent form of cell death. This is in con-
trast to cell death by necrosis, which is marked by cell lysis
and the release of inﬂammatory mediators. Although non-
apoptotic cell death pathways are sometimes considered as
secondary responses to apoptosis, there is growing evidence
that they can also be “programmed” and controlled by a
dedicated molecular circuitry. Moreover, these pathways
can be activated independently or as a consequence of
apoptosis inhibition [1].
Many forms of non-apoptotic RCD have been described
in recent years. These include necroptosis, parthanatos,
ferroptosis, mitochondrial permeability transition (MPT)-
dependent necrosis, pyroptosis and pyronecrosis, and
NETosis or ETosis [1]. The molecular mechanisms and
biological roles for some of these cell death modes are still
poorly deﬁned. By contrast, necroptosis has emerged as a
pivotal cell death response in microbial infections.
Necroptosis is initiated in response to toll-like receptor 3
(TLR3), TLR4, and death receptors in the tumor necrosis
factor receptor (TNFR) superfamily. Necroptosis is marked
by rupture of the plasma membrane and release of pro-
inﬂammatory damage-associated molecular patterns
(DAMPs) (Box 1). Hence, necroptosis is distinct from
apoptosis in both morphology and biological consequences
[2]. Receptor interacting protein kinase 3 (RIPK3) is a
serine/threonine kinase and key adaptor of necroptosis. In
addition to the kinase domain, RIPK3 also contains a “RIP
homotypic interaction motif (RHIM)” at the C-terminus. As
its name implies, the RHIM of RIPK3 mediates homotypic
interaction with other mammalian RHIM-containing signal
adaptors [3]. Consistent with the pro-inﬂammatory role of
necroptosis, RIPK3 has critical functions in microbial
infections [4]. Here, we discuss how viruses target RIPK3
and other components of the necroptosis pathway to
manipulate host-defense and anti-viral inﬂammation
(Table 1).
Necroptosis upon poxvirus infection
RIPK1, the upstream activator of RIPK3 in the TNF
receptor pathway, is a cleavage substrate of caspase 8.
Caspase 8 cleaves RIPK1 at D324, the boundary between
the N-terminal kinase domain and the C-terminal RHIM and
death domain [5]. The C-terminal cleavage product, which
contains the death domain, was reported to enhance apop-
tosis by promoting TRADD and FADD interaction [5].
However, since this cleavage event results in the release of
the kinase domain from the signaling complex, necroptosis
is inhibited. This explains why inhibition of caspase 8 is a
key priming signal for necroptosis. Although the supporting
biochemical evidence is still lacking, similar cleavage of
RIPK3 by caspase 8 has also been implicated [6, 7]. Large
DNA viruses often target caspases for inhibition, a strategy
that promotes viral persistence and immune evasion within
the host. For example, poxviruses encode serpins that
inhibit caspase 1 and caspase 8 [8]. Poxviral inhibition of
caspase 8 may therefore provide a natural priming signal for
necroptosis. Indeed, cells infected with vaccinia virus (VV),
the poxvirus strain that is used to vaccinate the world
population against smallpox, are highly sensitive to TNF-
induced necroptosis [9]. By contrast, VV-infected cells
deﬁcient in RIPK1 or RIPK3 were resistant to TNF-induced
necroptosis [10]. As a consequence, Ripk3−/− mice and
mice expressing the kinase-inactive RIPK1 mutant D138N
both failed to control VV replication in vivo [10, 11]. The
phenotypes of Ripk3−/− mice were reminiscent of mice
lacking TNF or TNF receptor expression [9]. These results
indicate that TNF, RIPK1, and RIPK3-dependent necrop-
tosis is a key innate immune host defense mechanism
against VV.
Box 1 Necroptosis signaling pathway
Although stimulated by several death ligands of the Tumor
necrosis factor (TNF) superfamily (TNFR1, Fas/CD95 and
TRAIL-R) and Toll-like receptors, TLR3 and TLR4, most of
our understanding of necroptosis comes from the studies of
TNFα/TNFR1 pathway. One of the key effects of TNFα/TNFR1
pathway is NF-κB transcriptional activation and its subsequent
pro-survival effects. The NF-κB activation takes place in the
plasma membrane-associated “Complex I”, which is assembled
upon death domain-mediated recruitment of TNFR1-associated
Death domain adaptor protein (TRADD), and receptor interacting
protein kinase 1 (RIPK1) (Fig. 1) [67]. Complex I assembly serves
as a central checkpoint for the induction of NF-κB, apoptosis and
necroptosis. E3 ligases such as cIAP1/2 and LUBAC mediate K63
and linear ubiquitination of RIPK1, ultimately resulting in IκBα
phosphorylation by IKKα/β and IκBα degradation. This liberates
NF-κB for nuclear translocation and transcription of inﬂammatory
effectors. The apoptotic function of TNFα signaling is mediated
through Fas-associated death domain (FADD) and pro-caspase 8 in
the cytoplasmic complex II [67]. The switch from complex I to
complex II is driven by the deubiquitination of RIPK1 by the
deubiquitinating enzyme CYLD (Fig. 1) [68]. Furthermore, in the
presence of caspase-8 inhibition, as seen in certain virus infections
[69], complex IIb, which is also known as the “necrosome”, is
formed. This complex is marked by the interaction of RIPK1 and
RIPK3 through their respective RHIM domains. This RHIM-
mediated interaction is marked by ﬁlamentous β-amyloid-like
conversion of the complex, which promotes robust necroptosis
signaling [70].
The execution of necroptosis requires RIPK3-induced phosphor-
ylation of mixed lineage kinase domain-like (MLKL) at Thr357
and Ser358 [71]. MLKL phosphorylation stimulates its oligomer-
ization, membrane translocation and rupture of the cell membrane
[72–74]. Several models have been proposed to explain the
membrane rupture activation of MLKL. These include the four α-
helix bundle (4HB) domain of MLKL promoting Ca2+ inﬂux
through TRPM7 channels [73] and MLKL contacting certain
phospholipids in the plasma membrane to form membrane-
penetrating pores [74].
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Interferon (IFN) response is a powerful host response
against pathogens. VV encodes many immune evasion
genes including those that neutralize the inﬂammatory
cytokines TNF and IFNs and other innate immune signaling
pathways. One of the VV-encoded immune modulators is
E3L, which contains a z-DNA binding domain that is also
found in the mammalian RHIM adaptor z-DNA binding
protein 1 (ZBP1, aka DAI for DNA activator of interferon).
Infection with VV expressing a truncated E3L lacking this
z-DNA binding domain led to increased ZBP1 expression
and excessive Type I IFN-induced RIPK3/MLKL-depen-
dent necroptosis. Moreover, the E3L mutant VV failed to
cause disease in wild type mice [12]. Strikingly, patho-
genicity was restored when the E3L mutant VV was used to
infect Ripk3−/− and Zbp1−/− mice [12]. These results indi-
cate that while TNF-induced, RIPK1/RIPK3/MLKL-medi-
ated necroptosis confers protection to the host,
E3L-mediated inhibition of ZBP1 and RIPK3 enables VV
to evade the anti-viral effects of IFNs (Fig. 1). The opposing
effects of the two RIPK3-driven responses suggest that the
timing and context of RIPK3-mediated necroptosis may
impact host response as well as viral growth and dis-
semination in the host.
Necroptosis upon herpesvirus infection
Cytomegalovirus
Herpesvirus is another large DNA virus family that
exploits the necroptosis pathway. In a forward genetic
screen using transposon mutagenesis, Brune and collea-
gues identiﬁed the murine cytomegalovirus (MCMV)
encoded M45 gene as a factor that promotes viral growth
and endothelial cell survival [13]. M45 encodes a large
polypeptide with homology to the large subunit of ribo-
nucleotide reductase (R1) at the C-terminus. However,
unlike other viral R1 subunits, M45 lacks enzymatic
activity [14]. In addition to the R1-like domain, M45
contains a RHIM at the N-terminus that mediates binding
to mammalian RHIM-containing adaptors such as RIPK1
and RIPK3 [15, 16]. In over-expression studies, M45
inhibited both TNF- and TLR3-driven NF-κB and MAPK
activation [15]. More recent studies showed that M45 also
inhibits necroptosis during MCMV infection. For exam-
ple, mutant MCMV expressing a M45 RHIM mutant
failed to replicate in cells due to excessive activation of
RIPK3-dependent necroptosis [17]. However, M45 was
only required for optimal viral replication in certain cell
types in tissue culture [18]. Mutant virus replication was
also compromised in the lungs, spleen, and salivary
glands of wild type mice. Thus, M45 is the ﬁrst viral
inhibitor of RIP activation (vIRA) identiﬁed. Strikingly,Ta
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Necroptosis in anti-viral inﬂammation
replication of the M45 RHIM mutant virus was restored in
Ripk3−/− or Zbp1−/− cells and mice [19], indicating that
M45 prevents premature cell death by inhibiting ZBP1/
RIPK3-induced necroptosis. In contrast to TNF-induced
necroptosis in VV-infected cells, RIPK1 is dispensable for
necroptosis induced by the M45 RHIM mutant MCMV
[17]. These results establish necroptosis as a bona ﬁde
host defense mechanism in MCMV. They also provide the
ﬁrst examples in which mammalian RHIM-containing
signal adaptors, other than RIPK1, activate RIPK3 and
necroptosis.
Recent studies suggest that MCMV transcription is
required for ZBP1-dependent necroptosis. When MCMV
transcription is inhibited at an early time point with che-
mical inhibitors, M45 RHIM mutant virus-infected cells
become resistant to necroptosis. The viral immediate early
protein 3 (IE3), a crucial transcriptional activator of
MCMV, was required for ZBP1 activation. Moreover,
mutation of key amino acid residues in the z-DNA binding
domain of ZBP1 abolished this response, suggesting that
ZBP1 activates necroptosis upon sensing viral nucleic acid
[20]. Hence, viral RNA, but not viral DNA, appears to be
the ligand that activates ZBP1 in response to MCMV
infection [21].
ZBP1 was originally identiﬁed as a sensor of viral DNA
that regulates virus-induced NF-κB activation and inter-
feron expression [22, 23]. However, DNA-induced IFN
expression was normal in Zbp1−/− macrophages, dendritic
cells and embryonic ﬁbroblasts [24]. Hence, it is note-
worthy that viral RNA sensing appears to be the key
mechanism by which ZBP1 becomes activated in response
to infection by mutant MCMV expressing a RHIM-mutated
M45/vIRA. As we shall see below, viral RNA sensing by
ZBP1 is also found in other viruses (Fig. 2). Hence, unlike
the TNF/RIPK1/RIPK3 necroptosis pathway, which has a
more prominent role in tissue homeostasis, ZBP1-mediated
necroptosis functions predominantly as a critical host
defense mechanism. These observations also argue strongly
that the ZBP1/RIPK3 necroptosis pathway may be the
product of host-pathogen co-evolution.
Besides M45, MCMV encodes another viral inhibitor
called vICA (for viral inhibitor of caspase 8-induced
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Fig. 1 Necroptosis in poxvirus infection. Control of vaccinia virus
(VV) infection requires TNF signaling [9]. TNF signaling through its
trimeric receptor (TNFR-1) triggers three distinct signaling responses:
NF-κB activation, apoptosis or necroptosis. Vaccinia virus encodes the
caspase inhibitor B13R/Spi2, which inhibits caspase 1 and caspase 8
and blocks apoptosis. Thus, in VV infection, TNF stimulation favors
necroptosis. This leads to assembly of the RHIM–RHIM interaction
between RIPK1–RIPK3 and necrosome formation. Certain viral FLIPs
such as MC159 from Molluscum contagious virus (MCV) inhibit both
apoptosis and necroptosis, although the mechanisms are not fully
elucidated. The VV-encoded protein E3L contains a z-DNA binding
domain that interacts with ZBP1 and senses viral RNA. E3L binding
sequesters ZBP1 from RIPK3 and therefore prevents necroptosis.
However, E3L does not interfere with TNF-induced necroptosis. VV
Vaccinia virus, TRADD TNFRSF1A associated death domain,
TRAF2 TNF receptor associated factor 2, cIAP cellular inhibitor of
apoptosis, CYLD cylindromatosis, FADD Fas associated via death
domain, IKK inhibitor of nuclear factor kappa B kinase, cFLIPL
CASP8 and FADD like apoptosis regulator long isoform, MLKL
mixed lineage kinase domain-like, RHIM RIP homotypic interaction
motif, Zα1, Zα2 zDNA binding domain
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apoptosis). vICA is encoded by the M36 gene. A recent
study indicates that M36 and M45 cooperate with each
other to suppress cell death-associated inﬂammation [18].
Infection of cells with mutant MCMV that lacks M36 and
M45 led to caspase 8 and RIPK3/MLKL activation and
severely reduced viral replication. The activation of RIPK3
and MLKL in the presence of intact caspase 8 activation is
interesting and signiﬁcant, since it challenges the paradigm
that necroptosis induction requires caspase 8 inhibition.
However, it is consistent with the involvement of ZBP1
rather than RIPK1 as the upstream activator of RIPK3 [19].
When compared to MCMV with single mutation in either
M36 or M45, M36/M45 double mutant virus elicited
stronger expression of many pro-inﬂammatory cytokines
and early CD8+ T cell activation [18]. These results high-
light the cooperative nature of apoptosis and necroptosis in
driving robust host anti-viral inﬂammation.
Similar to MCMV, human cytomegalovirus (HCMV)
also suppresses necroptosis induced by TNF, Smac
mimetics and caspase inhibitors. However, in contrast to
MCMV, HCMV does not inhibit RIPK3 phosphorylation,
and MLKL phosphorylation was readily detected [25].
These results indicate that HCMV interferes with necrop-
tosis at a step after MLKL activation. Consistent with the
notion that HCMV does not target ZBP1 or RIPK3, super-
infection with M45 RHIM mutant MCMV in HCMV-
infected cells no longer sensitize the cells to necroptosis.
While the precise mechanism by which HCMV inhibits
necroptosis is still unknown, viral gene products under the
control of the regulatory protein IE1 appear to be important,
since infection with mutant HCMV lacking IE1 no longer
conferred protection against TNF, Smac mimetic and cas-
pase inhibitor-induced necroptosis [25] (Fig. 2). It will be
interesting to determine if the differential mechanisms of
necroptosis inhibition by MCMV and HCMV is the driver
or consequence of viral evolution. It will also be important
to evaluate how this switch in cell death inhibitory
mechanism may inﬂuence anti-viral inﬂammation.
Other herpesviruses
Similar to cytomegaloviruses, the alpha herpesviruses
human herpes simplex virus 1 (HSV-1) and HSV-2 also
modulate necroptosis through the large subunit of the
ribonucleotide reductase (RR), ICP6 for HSV-1 and ICP10
for HSV-2. ICP6 and ICP10 share similar domain organi-
zation with M45, with an N-terminal RHIM and a C-
terminal RR. However, in contrast to M45, ICP6 and ICP10
retain intact ribonucleotide reductase function. In addition,
ICP6 and ICP10 interact with and inhibit caspase 8 [26].
IAV
M45 
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Kinase domain
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MLKL
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ZBP1
-
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vRNA
ZBP1
Fig. 2 Necroptosis in herpesvirus and Inﬂuenza virus infection. Her-
pesviruses exploit the necroptotic pathway via various RHIM adaptors
such as M45 from MCMV, ICP6 from HSV-1 and ICP10 from HSV-
2. These viral inhibitors sequester ZBP1 and RIPK3 to prevent their
interaction and activation. When viral RHIM inhibitors are absent,
ZBP1 senses viral RNA (vRNA) to trigger RIPK3 binding and acti-
vation. The necroptosis modulating function of these viral RHIM
adaptors varies with host species. For example, ICP6 and ICP10
prevent necroptosis in human cells, but stimulate RIPK3-dependent
necroptosis in mouse cells. Though the molecular basis for the dif-
ferential effects of ICP6 or ICP10 in different species is unknown, it
may account for the species tropism of these viruses. In contrast to
herpesvirus, IAV uses this mechanism to cause ZBP1/RIPK3-depen-
dent necroptosis. MCMV murine cytomegalovirus, HSV herpes sim-
plex virus, IAV Inﬂuenza A virus, vRNA viral RNA
Necroptosis in anti-viral inﬂammation
Thus, they are dual inhibitors of apoptosis and necroptosis.
The RHIM of ICP6 and ICP10 mediates RIPK1 and RIPK3
interaction [27–29]. HSV-1 triggered RIPK3/MLKL acti-
vation and necroptosis in mouse cells and increased viral
titers and mortality in mice [28]. By contrast, HSV-1 or
expression of ICP6 or ICP10 inhibits necroptosis in human
cells. The differential effects of ICP6 and ICP10 in human
versus mouse cells distinguish them from M45, which
potently inhibits necroptosis in both human and mouse
cells. Since HSV-1 and HSV-2 are human pathogens, the
differential activity of ICP6 and ICP10 may account for
their species tropism.
Epstein–Barr virus (EBV) is a gamma herpesvirus that
infects the majority of human adults. A recent report sug-
gests that the latent membrane protein 1 (LMP1) of EBV
interacts with RIPK1 and RIPK3, modulates their ubiqui-
tination status, and inhibits TNF, Smac mimetic and caspase
inhibitor-induced necroptosis [30]. Interestingly, a mapping
study using truncation mutants suggests that the interaction
between LMP1 and RIPK1 or RIPK3 is independent of the
RHIM. Further studies are required to conﬁrm this obser-
vation and to examine whether this interaction plays any
role in anti-viral immune responses and disease pathology.
Viral FLIPs and necroptosis
Like caspase 8, cellular FLICE (caspase 8)-like inhibitor
protein (cFLIP) contains two tandem death effector domains
at the N-terminus. However, the long form of cFLIP
(cFLIPL) harbors mutations at the C-terminal caspase
domain, thus rendering it enzymatically inactive. By con-
trast, the short form of cFLIP, cFLIPs, lacks the C-terminal
caspase domain. While cFLIPL promotes caspase 8 activa-
tion through heterodimerization, cFLIPs inhibits caspase 8
activity [31]. Interestingly, a class of viral FLIP proteins
(vFLIPs) has been identiﬁed in herpesviruses and the
human poxvirus Molluscum contagiosum virus (MCV) [32,
33]. vFLIPs lack the C-terminal caspase domain and thus
resemble cFLIPs in both structure and function [34, 35].
Surprisingly, many vFLIPs also exhibit necroptosis inhibi-
tory activity [9]. vFLIPs have been reported to interact with
RIPK1 [36]. However, we were not able to detect such
interaction (unpublished observation). Hence, the mechan-
ism by which vFLIPs inhibit necroptosis remains elusive.
Besides apoptosis and necroptosis, vFLIPs also interfere
with NF-κB activation. Several reports showed that trans-
genic expression of MC159 inhibited NF-κB activation and
triggered a loss of memory CD8+ T cells in mice [37, 38].
However, NF-κB inhibition requires high expression of
MC159. At low level of expression, MC159 actually sti-
mulates NF-κB activation [39]. In contrast to transgenic
mice expressing high level of MC159, mice with low
MC159 expression exhibited enhanced NF-κB activation,
chemokine expression and viral clearance in response to
VV infection [39]. The functional relevance of MC159 in
virus infection was further characterized by Hüttmann and
coworkers. When expressed in recombinant MCMV lacking
either M36 or M45, MC159 blocked TNF-induced apop-
tosis. However, necroptosis in human, but not mouse cells,
was inhibited by recombinant MCMV expressing MC159
[40]. These discrepant results highlight a potential caveat in
using over-expression to study viral necroptosis inhibitors
suggesting that their behavior can vary depending on the
expression level and the cell type studied.
Necroptosis in RNA virus infection
In a survey for additional viruses that might interfere with
necroptosis, Schock and colleagues found that Sendai virus
induced necroptosis in the presence of the pan-caspase
inhibitor zVAD-fmk [41]. Sendai virus drives necroptosis
via the RNA sensor RIG-I [41]. In Ripk3−/− mice, Sendai
virus infection resulted in increased inﬂammation. Although
more work is required to fully elucidate the mechanism by
which Sendai virus triggers necroptosis and inhibits
inﬂammation, these results do highlight the fact that RIPK3
does not always facilitate detrimental inﬂammation. Rather,
in certain situations such as that in Sendai virus infection,
RIPK3 can play an anti-inﬂammatory and protective role.
Recently, necroptosis has emerged as a critical pathway
in inﬂuenza virus-induced cell death and pathology. For
instance, Rodrigue-Gervais and coworkers found that
Birc3−/− mice, which are deﬁcient in the anti-apoptotic
factor cIAP2, were hypersensitive to inﬂuenza A virus
(IAV) infection and developed severe loss of lung epithe-
lium [42]. Importantly, pharmacologic inhibition of RIPK1
kinase activity or genetic deletion of Ripk3 rescued Birc3−/−
mice from IAV-induced epithelial necrosis, tissue damage
and lethality. These results are consistent with the known
function of cIAP1 and cIAP2 as apoptosis and necroptosis
inhibitors.
The study in Birc3−/− mice suggests a role for RIPK1
and RIPK3 in IAV pathogenesis. Indeed, several recent
studies indicate that RIPK3-dependent necroptosis plays a
key role in IAV-induced cell death. Similar to infection with
MCMV, ZBP1 functions as the upstream sensor of IAV
RNA to activate RIPK3 [43, 44]. ZBP1 was reported to
sense IAV nucleoprotein (NP) and polymerase subunit
(PB1) to induce necroptosis [43]. Interestingly, NP was also
reported to induce apoptosis in IAV-infected cells [45, 46].
In contrast to Birc3−/− mice, RIPK1 was mostly dispensable
for IAV-induced cell death in wild type cells or mice [47].
Ripk3−/− and Zbp1−/− mice failed to control viral replica-
tion and exhibited increased mortality in response to IAV
infection [44, 48]. However, increased mortality was not
observed in another report [43].
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Mechanistically, IAV-induced expression of cytokines
such as type I IFNs via RIPK3 and ZBP1. As such, IAV-
induced IFNβ expression was impaired in Ripk3−/− and
Zbp1−/− cells [43]. While reduced IFNβ expression might
be due to decreased necroptosis and necroptosis-driven
inﬂammation, it could also be caused by direct effects on
gene transcription [49–53]. For example, in West Nile virus
infection, chemokine expression in the central nervous
system was driven by RIPK3 but independent of cell death
[52]. In macrophages, IAV induced binding between RIPK3
and the mitochondrial associated RNA sensor MAVS,
which stimulated TBK1 and IRF1/IRF3 activation to pro-
mote IFNβ mRNA stability [48, 54]. This response is not
only critical for virus-induced IFN expression, but also for
the expression of the necroptosis genes Zbp1 and Mlkl. The
relative contribution of cell death-dependent and indepen-
dent activities of RIPK3 in inﬂuenza virus infection will
require further investigation.
Further evidence supporting a role for RIPK3-dependent
necroptosis in shaping inﬂuenza virus-induced pathogenesis
comes from a recent study comparing the host response to
seasonal versus pandemic strains of IAV. Remarkably,
virus-induced necroptosis in dendritic cells (DCs) was
readily detected by seasonal IAV strains, but not by pan-
demic IAV strains [55]. In co-culture experiments, seasonal
IAV-infected DCs underwent necroptosis and induced
bystander DC maturation and virus-speciﬁc T cell pro-
liferation. By contrast, DC maturation and T cell pro-
liferation were signiﬁcantly impaired in pandemic IAV-
infected DC cultures. At present, the molecular mechanism
by which seasonal and pandemic IAV strains induces dif-
ferential necroptosis in DCs is unknown. However, differ-
ences in the viral hemagglutinin gene segment between the
two groups of IAVs have been implicated [55]. These
results highlight the interesting scenario that necroptosis
may have broad functions in shaping viral evolution and
pathogenicity.
To further complicate matters, recent studies have
clearly demonstrated a necroptosis-independent role for
RIPK3 inNLRP3 inﬂammasome activation [56]. Inﬂam-
masome activation results in two major biological out-
comes: processing and secretion of pro-inﬂammatory
cytokines IL-1β and IL-18, and induction of pyroptosis,
another lytic form of cell death [57]. RIPK3-mediated
inﬂammasome activity has been reported to promote IL-1β
secretion in response to IAV, Sendai virus and Vesicular
stomatitis virus (VSV). Interestingly, the mitochondrial
ﬁssion protein DRP1 was implicated to signal downstream
of RIPK3 to promote RNA virus-induced inﬂammasome
activity [58]. However, these results were challenged by
another study, which showed that VSV-induced IL-1β
secretion was normal in Ripk3−/−macrophages and mac-
rophages expressing the kinase inactive RIPK3 mutant
K51A [59]. Nonetheless, the artiﬁcial ligand for TLR3 and
RIG-I poly(I:C), which mimics viral double-stranded
RNA, could clearly activate RIPK3 signaling, especially
in the presence of caspase inhibition [60–62]. Thus, we
cannot rule out the possibility that RIPK3 can indeed sti-
mulate inﬂammasome activation in certain situations. In
this light, it is noteworthy that RIPK3-dependent inﬂam-
masome activity was particularly prominent in human
monocytes, mouse dendritic cells and macrophages
[49, 63, 64]. Thus, the anti-viral mechanism employed by
RIPK3 in response to different pathogens will likely vary
depending on the cell type under investigation.
Conclusion
Research in the last decade has clearly established necrop-
tosis as a crucial host defense response against many
pathogens. In response, viruses have developed different
strategies to neutralize the host necroptosis machinery. In
addition to viral pathogens, an increasing number of non-
viral pathogens have also been found to target the necrop-
tosis machinery. For example, atypical proteases from cer-
tain pathogenic bacteria speciﬁcally target mammalian
RHIM-containing signal adaptors for cleavage and inacti-
vation [65]. An important lesson we learned from studies
with different pathogens is that while apoptosis and
necroptosis are often mutually exclusive responses in tissue
culture, this is not the case in pathogen infections. For
instance, IAV infection elicits concomitant activation of
caspase-dependent apoptosis and RIP kinase-mediated
necroptosis [66]. The cooperative nature of apoptosis and
necroptosis in anti-microbial defense is further illustrated by
the fact that caspase 8, its adaptor FADD, RIPK1 and
RIPK3 are often found in the same signaling complex
regardless of whether apoptosis or necroptosis is the
dominant response. This concept is further bolstered by the
many examples in which pathogens often target both
pathways of cell death. The knowledge gained from
studying how various pathogens counteract the host cell
death machinery may lead us to better therapeutic strategies
against viral and sterile inﬂammatory diseases.
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